Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects

Estimation of Microstructure Alteration by MRI in Dementia Among Elderly Subjects Retired From Agricultural Profession and Living in Rural Area in Gironde - Participants From the AMI Cohort.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00951197

Acronym

AMIMAGE

Enrollment

318

Registered

2009-08-04

Start date

2009-04-30

Completion date

2011-03-31

Last updated

2012-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Dementia

Keywords

dementia, Alzheimer's Disease, diagnostic, biomarkers, neuroimaging, PET, MRI, mild cognitive impairment

Brief summary

Capturing the earliest stages of Dementia especially Alzheimer's Disease (AD) is a great challenge. Until now the NINCDS-ADRDA and the DSM criteria for AD were largely used as diagnostic standards in research. However, the research on AD progresses and some biomarkers have been recently suggested to improve the diagnostic criteria of AD, such as cerebrospinal fluid markers, neuroimaging with Positon Emission Tomography (PET) or Magnetic Resonance Imaging (MRI).

Interventions

OTHERNeuroimaging

Three successive MRI acquisitions to measure FA, MTR and T2 parameters.

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* participate in the AMI cohort * be aged 65 and older * be retired from agricultural profession * live in rural area in Gironde

Exclusion criteria

* contraindication of MRI * left-handed * severe dementia * Parkinson's disease * poor health incompatible with the transport to neuroimaging service * to be left handed

Design outcomes

Primary

Measure	Time frame
FA (Fractional Anisotropy), MTR (magnetization transfer ratio) and T2 (Transverse relaxation time) measures in patients with dementia compared to controls, in left and right hippocampus, and posterior cingulum	day 0

Secondary

Measure	Time frame
FA, MTR and T2 measures in subjects with mild cognitive impairment no dementia	day 0
Performances in the 7 neuropsychological tests available in the AMI cohort	day 0
FA measures for the connexion Hippocampus-cingulum posterior	day 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026